CSL (ASX:CSL) has posted its half-year results, delivering results that are best described as mixed. At the headline level, ...

Laser-produced plasmas have been used to create short bursts of x-rays and to accelerate particles — so-called plasma-based accelerators. Laser produced plasmas are also useful for recreating ...

CSL’s balance sheet is in sound condition. Financial risk is low given low revenue cyclicality and product demand is being largely driven by chronic indications. We forecast CSL’s net debt to EBITDA ...

Plasma Fractionation Market Share 2025 Plasma fractionation is a process of separating various components of plasma, which in turn is a com ...

CSL has reported a 7% net profit rise for the December half, with its blood-derived products offsetting weak flu vaccination ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.

This image is from the post Panasonic Singapore December 2010 Christmas Promotion Sale Price List. Click the link to view the original article and possibly more related images. 7-Eleven S’pore New Ice ...

Learn More If you have been thinking about buying CSL Ltd (ASX: CSL) shares, then read on. That's because Goldman Sachs has just named another reason to buy the biotechnology giant's shares.

#1. CSL Key milestones: 2007: CSL hit $100 before its 3-for-1 split. 2015: CSL hit $100 (again) 2018: Cracked $200. 2020: First surpassed $300. Note: CSL would technically be above $500 were it not ...